West Pharmaceutical Services (NYSE:WST) Issues Quarterly Earnings Results, Beats Estimates By $0.07 EPS

West Pharmaceutical Services (NYSE:WST) posted its quarterly earnings data on Thursday. The medical instruments supplier reported $1.82 earnings per share for the quarter, topping analysts’ consensus estimates of $1.75 by $0.07, Zacks reports. West Pharmaceutical Services had a return on equity of 18.41% and a net margin of 17.37%. West Pharmaceutical Services updated its FY 2025 guidance to 6.000-6.200 EPS.

West Pharmaceutical Services Stock Down 36.9 %

West Pharmaceutical Services stock traded down $118.99 during midday trading on Thursday, hitting $203.29. 2,970,519 shares of the stock were exchanged, compared to its average volume of 538,771. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.00 and a quick ratio of 2.23. The company has a 50 day moving average price of $332.39 and a two-hundred day moving average price of $315.13. The firm has a market cap of $14.72 billion, a P/E ratio of 30.34, a P/E/G ratio of 19.31 and a beta of 1.01. West Pharmaceutical Services has a 1 year low of $201.99 and a 1 year high of $408.88.

West Pharmaceutical Services Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, February 11th. Stockholders of record on Friday, February 7th were paid a dividend of $0.21 per share. The ex-dividend date of this dividend was Friday, February 7th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.41%. West Pharmaceutical Services’s dividend payout ratio is currently 12.46%.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on WST shares. StockNews.com raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research note on Tuesday. Wolfe Research started coverage on shares of West Pharmaceutical Services in a research report on Friday, December 13th. They issued a “peer perform” rating for the company. UBS Group raised West Pharmaceutical Services from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $350.00 to $390.00 in a research report on Thursday, December 12th. Citigroup assumed coverage on shares of West Pharmaceutical Services in a research report on Wednesday, January 8th. They issued a “buy” rating and a $400.00 target price on the stock. Finally, Bank of America boosted their price target on West Pharmaceutical Services from $350.00 to $355.00 and gave the company a “buy” rating in a research report on Friday, December 13th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $403.75.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.